So as you previously explained other drugs in very much detail…similary teach me snri, each drug in detail , ndri, and serotonin modulators,…in very much detail- history, mechanism of action, phamakokinetics dynamics, indications contraindication, side effect, safety profile, recent advances, toxicity, guidelines and uses formulations and dosages, administrroutes, drug interactions, special population and discontinuation syndromes
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Good, I found the key textbook sections. Now let me read the primary comprehensive sections from Stahl's, Goodman & Gilman's, Kaplan & Sadock's, and Katzung's simultaneously.
Reading File
Reading File
Reading File
Reading File
Searching PubMed
SNRIs antidepressants venlafaxine duloxetine clinical review
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Searching PubMed
bupropion antidepressant smoking cessation
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
I now have comprehensive data from multiple authoritative textbooks. Let me synthesize this into a detailed, well-organized teaching document.
SNRIs, NDRIs & Serotonin Modulators — A Complete Pharmacology Guide
PART I: SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs)
Class Overview
History: SNRIs emerged from the search for antidepressants that could outperform SSRIs by targeting two monoamine systems simultaneously. Venlafaxine was the first agent, approved by the FDA in 1993, followed by milnacipran (1997, Europe), duloxetine (2004), desvenlafaxine (2008), and levomilnacipran (2013). The rationale was that dual monoamine enhancement might increase remission rates — and head-to-head trials suggest venlafaxine's remission rate is indeed slightly superior to SSRIs. (Goodman & Gilman's, p. 365)
Class mechanism: SNRIs block the presynaptic serotonin transporter (SERT) and norepinephrine transporter (NET), preventing reuptake and increasing synaptic concentrations of both 5-HT and NE. Unlike TCAs, they have minimal activity at α-adrenergic, muscarinic, or histamine receptors — so fewer receptor-mediated adverse effects. To a lesser extent, some also weakly inhibit dopamine reuptake via DAT. (Lippincott, p. 585)
1. VENLAFAXINE (Effexor®)
History
Synthesized by Wyeth Pharmaceuticals and approved by the FDA in 1993, venlafaxine was the first SNRI. The extended-release formulation (Effexor XR) was approved in 1997 and is now the dominant formulation in clinical practice.
Mechanism of Action
Venlafaxine is a dose-dependent dual reuptake inhibitor:
- At low doses (75 mg/day): predominantly inhibits SERT → SSRI-like effect
- At medium doses (150 mg/day): meaningful NET inhibition begins
- At high doses (225–375 mg/day): full dual SNRI effect, and weak DAT inhibition as well
This dose-dependence makes venlafaxine unique. Its antidepressant and anxiolytic effects at low doses are primarily serotonergic, while noradrenergic effects (increased energy, improved concentration, analgesic benefit) emerge at higher doses. (Lippincott, p. 586)
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Bioavailability | ~45% (IR), higher with XR formulation |
| Protein binding | ~27% (low — important in overdose) |
| Metabolism | Hepatic via CYP2D6 → active metabolite desvenlafaxine (ODV) |
| Half-life | Venlafaxine: ~5 hours; ODV: ~11 hours |
| Elimination | Primarily renal (87%) |
| Active metabolite | O-desmethylvenlafaxine (ODV) = desvenlafaxine |
Minimal inhibition of CYP450 isoenzymes — so relatively fewer drug interactions than paroxetine or fluoxetine.
Formulations & Dosing
| Formulation | Starting dose | Therapeutic range | Max |
|---|---|---|---|
| Effexor IR (bid-tid) | 37.5–75 mg/day | 75–225 mg/day | 375 mg/day |
| Effexor XR (once daily) | 37.5–75 mg/day | 75–225 mg/day | 225 mg/day |
| Generic capsules/tablets | Available | — | — |
Depression: 75–225 mg/day
GAD/Social anxiety/Panic: 75–225 mg/day
PTSD (off-label): 75–300 mg/day
Neuropathic pain (off-label): 75–225 mg/day
Hot flashes (off-label): 37.5–75 mg/day
Migraine prevention (off-label): 75–150 mg/day
GAD/Social anxiety/Panic: 75–225 mg/day
PTSD (off-label): 75–300 mg/day
Neuropathic pain (off-label): 75–225 mg/day
Hot flashes (off-label): 37.5–75 mg/day
Migraine prevention (off-label): 75–150 mg/day
Administration Routes
Oral only. XR capsules can be opened and sprinkled on food for patients who cannot swallow capsules. Do not crush extended-release tablets.
Indications
- FDA-approved: Major depressive disorder (MDD), Generalized anxiety disorder (GAD), Social anxiety disorder (SAD), Panic disorder
- Off-label: PTSD, ADHD, hot flashes, migraine prophylaxis, neuropathic pain, premenstrual dysphoric disorder (PMDD), fibromyalgia, binge-eating disorder
Contraindications
- Concurrent use with MAOIs (or within 14 days of discontinuing an MAOI — risk of serotonin syndrome)
- Use with linezolid or IV methylene blue (serotonin syndrome risk)
- Hypersensitivity to venlafaxine
Side Effects & Safety Profile
| System | Effect |
|---|---|
| GI | Nausea (most common, dose-related, usually transient), dry mouth, constipation |
| CNS | Insomnia, headache, dizziness, somnolence |
| Sexual | Decreased libido, anorgasmia, ejaculatory dysfunction |
| CV | Dose-dependent elevation in blood pressure and heart rate (unique to SNRIs at higher doses) |
| Other | Diaphoresis, mydriasis, weight neutral to slight loss |
Blood pressure elevation is a distinctive feature of venlafaxine vs. SSRIs. At doses >300 mg/day, ~13% of patients experience sustained diastolic hypertension. Monitor BP regularly, especially at high doses.
Drug Interactions
- Serotonin syndrome: MAOIs, triptans, tramadol, linezolid, methylene blue, other serotonergic agents
- CNS depression: additive with alcohol, benzodiazepines, opioids
- CYP2D6 inhibitors (fluoxetine, paroxetine): increase venlafaxine levels
- Anticoagulants (warfarin, aspirin, NSAIDs): increased bleeding risk due to platelet serotonin depletion
Special Populations
- Pregnancy: Category C. 2022 meta-analysis concluded SNRIs are not major teratogens, but neonatal adaptation syndrome (jitteriness, poor feeding, mild respiratory distress) can occur in neonates exposed in the third trimester. (Maudsley, p. 2168)
- Breastfeeding: excreted in breast milk; use with caution, weigh risk-benefit
- Elderly: start low (37.5 mg), monitor blood pressure; risk of falls and SIADH/hyponatremia
- Renal impairment: reduce dose by 25–50% if CrCl <30 mL/min
- Hepatic impairment: reduce total daily dose by 50% in mild-moderate impairment
- Children/Adolescents: FDA black box warning — increased risk of suicidal ideation in patients <24 years; not FDA-approved in pediatric patients for MDD
Toxicity / Overdose
Venlafaxine overdose is more dangerous than SSRI overdose due to its cardiovascular effects:
- QTc prolongation, tachycardia, hypertension
- Seizures (at toxic doses)
- Serotonin syndrome
- CNS depression → coma
Management: supportive care, cardiac monitoring, benzodiazepines for seizures, cyproheptadine for serotonin syndrome. Low protein binding (27%) means it is NOT effectively dialyzed.
Discontinuation Syndrome
Very significant — one of the most pronounced among antidepressants due to the short half-life (~5–11 hours). Symptoms appear within 24–48 hours of abrupt cessation:
- FINISH mnemonic: Flu-like symptoms, Insomnia, Nausea, Imbalance/dizziness, Sensory disturbances ("brain zaps," electric shock sensations), Hyperarousal/anxiety
- Taper slowly over weeks to months; some patients require a switch to fluoxetine (long half-life) to facilitate tapering. (Maudsley Deprescribing Guidelines)
Recent Advances
- Venlafaxine is now established as a first-line agent for menopausal vasomotor symptoms in women who cannot take hormones
- Growing evidence for its use in breast cancer patients experiencing treatment-induced neuropathic pain
- Studies exploring its role in ADHD (off-label)
2. DESVENLAFAXINE (Pristiq®)
History
Desvenlafaxine is the O-desmethyl major active metabolite of venlafaxine, developed and approved by the FDA in 2008 as a standalone antidepressant. Its rationale: consistent pharmacokinetics regardless of CYP2D6 genotype.
Mechanism of Action
Same dual SNRI mechanism as venlafaxine, but does NOT require metabolic activation. Inhibits both SERT and NET at all therapeutic doses — unlike venlafaxine, there is no low-dose serotonin-preferential phase. Ratio of NE:5HT potency is ~10:1 for venlafaxine; desvenlafaxine is more balanced.
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Bioavailability | ~80% (much higher than venlafaxine due to no first-pass effect) |
| Protein binding | ~30% |
| Metabolism | Conjugation (glucuronidation) — minimal CYP involvement |
| Half-life | ~11 hours |
| Elimination | Renal (45% unchanged in urine) |
Not a significant CYP inhibitor. Consistent levels regardless of CYP2D6 genotype status (poor vs. extensive metabolizer) — this is a clinical advantage over venlafaxine.
Formulations & Dosing
- Available as extended-release tablets (25 mg, 50 mg, 100 mg)
- Standard dose: 50 mg once daily (FDA-approved dose for MDD)
- Doses above 50 mg/day provide no additional antidepressant benefit but increase side effects
Do NOT crush or split extended-release tablets.
Indications & Uses
- FDA-approved: MDD
- Off-label: Vasomotor symptoms of menopause, fibromyalgia, chronic pain
- Clinical activity and adverse effect profile essentially identical to venlafaxine. (Lippincott, p. 586)
Special Populations
- Renal impairment: dose reduction required — max 50 mg every other day if severe impairment (CrCl <30 mL/min)
- Elderly: no dose adjustment strictly required, but start low given fall and hyponatremia risk
- Pregnancy/breastfeeding: similar precautions to venlafaxine
Discontinuation
Shorter half-life than fluoxetine — discontinuation syndrome risk is real but somewhat less severe than venlafaxine IR. Taper over at least 2–4 weeks.
3. DULOXETINE (Cymbalta®)
History
Developed by Eli Lilly, duloxetine received FDA approval in 2004 for MDD and diabetic peripheral neuropathic pain (DPNP), making it the first antidepressant explicitly approved for a pain indication. It subsequently gained approvals for fibromyalgia (2008), GAD (2007), and chronic musculoskeletal pain (2010).
Mechanism of Action
Duloxetine is a potent, balanced, dose-independent SNRI — it inhibits both SERT and NET equally at all therapeutic doses. It does not depend on dose escalation to engage noradrenergic effects, unlike venlafaxine. This makes it particularly effective for pain syndromes mediated by descending NE/5-HT modulatory pathways. (Kaplan & Sadock's, p. 3245)
Ratio of SERT:NET inhibition ~10:1 for duloxetine (slightly serotonin-preferential in vitro, but clinically balanced).
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Bioavailability | ~50% (oral) |
| Protein binding | >90% (highly protein-bound) |
| Metabolism | Hepatic — CYP1A2 and CYP2D6 |
| Half-life | ~12 hours |
| Active metabolites | None clinically significant |
| Elimination | Urine (~70%) and feces (~20%) |
Avoid in hepatic impairment — duloxetine is extensively metabolized to inactive metabolites and should be avoided in patients with liver dysfunction (including heavy alcohol use). (Lippincott, p. 586)
Formulations & Dosing
| Indication | Starting dose | Target dose | Max |
|---|---|---|---|
| MDD | 30–60 mg once daily | 60 mg/day | 120 mg/day |
| GAD | 30–60 mg once daily | 60 mg/day | 120 mg/day |
| Diabetic neuropathy | 60 mg once daily | 60 mg/day | 120 mg/day |
| Fibromyalgia | 30 mg/day × 1 week, then 60 mg | 60 mg/day | 120 mg/day |
| Chronic MSK pain | 60 mg once daily | 60 mg/day | 120 mg/day |
| Stress urinary incontinence (Europe) | 20–40 mg bid | 40 mg bid | — |
Capsules should be swallowed whole (not crushed or opened, due to enteric coating protecting against GI irritation). Can be taken with food to minimize nausea.
Indications
- FDA-approved: MDD, GAD, diabetic peripheral neuropathic pain, fibromyalgia, chronic musculoskeletal pain
- Off-label: Stress urinary incontinence (approved in EU as Yentreve), chemotherapy-induced neuropathy, PTSD, osteoarthritis pain, low back pain
Contraindications
- MAOIs (serotonin syndrome)
- Uncontrolled narrow-angle glaucoma
- Hepatic insufficiency / heavy alcohol use
- Hypersensitivity
Side Effects
| System | Effect |
|---|---|
| GI | Nausea, constipation, dry mouth (very common) |
| CNS | Insomnia, dizziness, somnolence, headache |
| Sexual | Decreased libido, anorgasmia |
| Sweating | Diaphoresis |
| CV | Mild BP and HR elevation |
| Hepatic | Rare hepatotoxicity (monitor LFTs if risk factors) |
Moderate CYP2D6 inhibitor — may increase concentrations of antipsychotics, TCAs, and other CYP2D6 substrates. (Lippincott, p. 586)
Drug Interactions
- MAOIs: serotonin syndrome
- CYP1A2 inhibitors (fluvoxamine, ciprofloxacin): significantly increase duloxetine levels → reduce dose
- CYP2D6 inhibitors (paroxetine): further increase duloxetine exposure
- Thioridazine: absolute contraindication (QTc prolongation + duloxetine-mediated CYP2D6 inhibition raising thioridazine levels)
- NSAIDs/anticoagulants: increased bleeding risk
- Alcohol: additive hepatotoxicity risk; avoid combination
Special Populations
- Hepatic impairment: avoid — no reliable dose adjustment available
- Renal impairment (severe, CrCl <30): avoid or use lowest dose
- Elderly: effective and widely used; especially for MDD with comorbid pain; hyponatremia risk
- Pregnancy: neonatal adaptation syndrome; not teratogenic per 2022 meta-analysis
Discontinuation
Significant discontinuation syndrome due to ~12-hour half-life. Taper over at least 4–8 weeks; some patients require 3–6 months of tapering. "Brain zaps," dizziness, nausea are common.
4. LEVOMILNACIPRAN (Fetzima®)
History
Levomilnacipran is the more active (1S,2R)-enantiomer of milnacipran, approved by the FDA in 2013 for MDD. Milnacipran itself is approved in the US specifically for fibromyalgia (Savella®) but not for MDD (though it is used for depression in Europe and Japan).
Mechanism of Action
Unique among SNRIs: levomilnacipran preferentially inhibits NET over SERT (NE:5HT ratio approximately 2:1 — the inverse of most SNRIs). This means it has a more pronounced noradrenergic profile than other SNRIs, potentially beneficial for fatigue, concentration, and physical symptoms of depression.
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Bioavailability | ~92% |
| Protein binding | ~22% (low) |
| Metabolism | CYP3A4 (major) |
| Half-life | ~12 hours |
| Elimination | Primarily renal (58% unchanged) |
Low protein binding + primarily renal elimination distinguishes it from duloxetine.
Formulations & Dosing
- Extended-release capsules: 20 mg, 40 mg, 80 mg, 120 mg
- Starting dose: 20 mg once daily × 2 days, then 40 mg once daily
- Therapeutic range: 40–120 mg once daily
- Max dose: 120 mg/day (reduce to 80 mg/day in moderate renal impairment; avoid in severe renal impairment)
Indications
- FDA-approved: MDD only
- Particularly studied for the physical/somatic symptoms of depression (fatigue, pain, cognitive sluggishness)
Side Effects
Similar to other SNRIs: nausea, headache, dry mouth, constipation, hyperhidrosis, tachycardia, erectile dysfunction, palpitations. Due to stronger NE effects, cardiovascular effects (tachycardia, BP elevation) may be more prominent.
Drug Interactions
- Strong CYP3A4 inhibitors (ketoconazole, ritonavir): increase levomilnacipran levels → do not exceed 80 mg/day
- MAOIs: contraindicated
5. MILNACIPRAN (Savella®)
History
Originally developed in France (1996) for depression. In the US, FDA approved it in 2009 specifically for fibromyalgia — a unique niche. Not approved for depression in the US despite extensive European use.
Mechanism of Action
Balanced dual SNRI with a slight NE preference. Like levomilnacipran, it reduces hyperalgesia mediated by monoamine and opioid systems, making it effective for fibromyalgia. (Kaplan & Sadock's, p. 3245)
Pharmacokinetics
- Bioavailability: ~85%
- Half-life: ~8 hours
- Metabolism: minimal hepatic (mainly glucuronidation), no significant CYP involvement
- Elimination: primarily renal (55% unchanged)
Dosing (Fibromyalgia)
- Day 1: 12.5 mg once
- Days 2–3: 12.5 mg twice daily
- Days 4–7: 25 mg twice daily
- After week 1: 50 mg twice daily (target = 100 mg/day)
- Max: 200 mg/day (not well-supported)
Class-Wide SNRI Considerations
Shared Side Effects
- Nausea (most common early side effect — take with food, typically improves within 2 weeks)
- Sexual dysfunction (decreased libido, delayed orgasm, ED)
- Dizziness, headache
- Diaphoresis
- Dose-dependent blood pressure and heart rate increases
- SIADH/hyponatremia (especially in elderly — monitor sodium at baseline and 2–4 weeks after initiation)
Serotonin Syndrome
Occurs with combinations of serotonergic agents. Features: agitation, clonus, hyperthermia, tachycardia, diaphoresis, diarrhea. Severe cases: rhabdomyolysis, seizures, death. Treatment: discontinue offending agent, supportive care, cyproheptadine (5-HT2 antagonist).
Black Box Warning (all antidepressants)
Increased risk of suicidal ideation and behavior in children, adolescents, and young adults (up to age 24) especially in early treatment. Monitor closely for worsening depression, agitation, or suicidal thoughts.
SNRI in Chronic Pain
SNRIs are superior to SSRIs for pain — NE and 5-HT modulate descending pain inhibitory pathways in the dorsal horn. Both duloxetine and milnacipran have Level A evidence for fibromyalgia. Duloxetine is first-line for diabetic peripheral neuropathy. Venlafaxine reduces neuropathic pain in various settings. (Kaplan & Sadock's, p. 3245)
PART II: NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITOR (NDRI)
BUPROPION (Wellbutrin®, Zyban®)
History
Bupropion was synthesized by Nariman Mehta at Burroughs Wellcome in 1969 as an aminoketone antidepressant. It was first approved by the FDA in 1985 but was temporarily withdrawn in 1986 when post-marketing seizures emerged at high doses, particularly in patients with bulimia nervosa. It was re-approved in 1989 with tighter dosing guidelines. The sustained-release formulation (Wellbutrin SR) was approved in 1996, and extended-release (Wellbutrin XL) in 2003. Zyban® (same molecule) was approved for smoking cessation in 1997. The combination product Auvelity® (bupropion + dextromethorphan) was approved in 2022 for MDD.
Mechanism of Action
Bupropion is a weak inhibitor of both DAT and NET — the prototypical NDRI. It does NOT inhibit SERT and has no serotonergic activity.
Key mechanisms (Stahl's, p. 319–320):
- Weak DAT blockade in striatum → increases dopamine
- Weak NET blockade in prefrontal cortex → increases NE and DA (DA has no transporter in PFC, so NET blockade secondarily increases DA there)
- Active metabolites (especially hydroxybupropion / radafaxine) are more potent NET inhibitors and are concentrated in the brain — bupropion acts partly as a prodrug
- Nicotinic acetylcholine receptor (nAChR) antagonism — contributes to smoking cessation efficacy by blunting nicotine's reward signal
PET studies show only 10–30% DAT/NET occupancy at therapeutic doses — much less than the 90%+ seen with stimulants. This likely explains its low abuse potential despite dopaminergic activity.
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Bioavailability | ~5–20% (extensive first-pass) |
| Protein binding | ~84% |
| Metabolism | CYP2B6 (primary) → hydroxybupropion (most potent active metabolite), threohydrobupropion, erythrohydrobupropion |
| Half-life (bupropion) | ~21 hours (XL); ~12 hours (SR); ~8–10 hours (IR) |
| Half-life (hydroxybupropion) | ~20 hours |
| Elimination | Urine (87%), feces (10%) |
CYP2B6 pathway: few major inhibitors (ritonavir, ticlopidine) and inducers (rifampin, carbamazepine) — hence relatively low drug interaction risk. Bupropion itself is a CYP2D6 inhibitor (moderate) — can raise levels of substrates like TCAs, antipsychotics, codeine.
Formulations & Dosing
| Formulation | Frequency | Starting dose | Target | Max |
|---|---|---|---|---|
| IR (Wellbutrin) | TID | 100 mg bid × 3 days, then 100 mg tid | 300 mg/day | 450 mg/day |
| SR (Wellbutrin SR) | BID | 150 mg qd × 3 days, then bid | 300 mg/day | 400 mg/day |
| XL (Wellbutrin XL) | Once daily | 150 mg/day × 3–7 days | 300 mg/day | 450 mg/day |
| Zyban® (SR, smoking cessation) | BID | 150 mg/day × 3 days, then 150 mg bid | 300 mg/day | 300 mg/day |
| Auvelity® (bupropion/dextromethorphan) | Once-twice daily | 45 mg/105 mg × 3 days, then twice daily | 90/210 mg bid | — |
No single dose of IR should exceed 150 mg (seizure risk is dose- and peak-concentration-dependent).
Indications
- FDA-approved:
- MDD (all formulations)
- Seasonal affective disorder (XL formulation)
- Smoking cessation (Zyban® SR)
- MDD (Auvelity® — bupropion + dextromethorphan combination, 2022)
- Off-label:
- ADHD (especially in adults; evidence for both adult and pediatric ADHD)
- Bipolar depression (adjunct)
- Sexual dysfunction induced by SSRIs/SNRIs
- Obesity/weight loss
- Neuropathic pain
- Fatigue in multiple sclerosis
- Hypersomnia
Contraindications (critical)
- Seizure disorder — bupropion lowers seizure threshold dose-dependently
- Current or history of anorexia nervosa or bulimia nervosa — electrolyte abnormalities lower seizure threshold further; withdrawal seizures in this population led to original market withdrawal
- Abrupt discontinuation of alcohol, benzodiazepines, or antiepileptics — increases seizure risk
- MAOIs — within 14 days (risk of hypertensive crisis, not serotonin syndrome per se)
- Linezolid, IV methylene blue
- Hypersensitivity
Side Effects & Safety Profile
| System | Effect | Notes |
|---|---|---|
| CNS | Dry mouth, insomnia, headache, nervousness, tremor, agitation | Very common |
| Seizures | Dose-dependent, ~0.1% at ≤300 mg/day; ~0.4% at 400 mg; ~4% at 600 mg | Major safety concern |
| GI | Dry mouth, nausea, constipation | Dry mouth is very common |
| CV | Mild tachycardia, BP elevation | Less than SNRIs |
| Weight | Weight neutral to weight loss | Major advantage |
| Sexual | Very low incidence of sexual dysfunction | Key differentiating feature |
| Diaphoresis | Sweating | Common |
No sexual dysfunction is one of bupropion's most clinically significant advantages — it is commonly added to SSRI/SNRI regimens to counteract antidepressant-induced sexual dysfunction.
Drug Interactions
- MAOIs: absolute contraindication
- CYP2D6 substrates (TCAs, antipsychotics, metoprolol, codeine): bupropion inhibits CYP2D6 → may increase their levels
- CYP2B6 inducers (carbamazepine, rifampin, phenytoin): decrease bupropion levels
- Levodopa, amantadine: increased dopaminergic side effects
- Linezolid, methylene blue: contraindicated
- Alcohol: seizure risk if bupropion used and alcohol suddenly withdrawn
- Tamoxifen: bupropion (via CYP2D6 inhibition) may impair conversion of tamoxifen to its active form endoxifen — significant oncology drug interaction
Special Populations
- Elderly: generally well tolerated; advantageous due to minimal anticholinergic effects, no orthostasis, no sedation, no significant cardiac effects; dose adjustments needed for severe renal/hepatic disease
- Children/Adolescents: black box warning for suicidality; used off-label for pediatric ADHD and depression
- Pregnancy: FDA Category C; limited data; no convincing teratogenic signal; compatible with breastfeeding at most doses
- Renal/Hepatic impairment: reduce dose and frequency; longer half-life of metabolites → accumulation risk
- Patients with eating disorders: absolute contraindication (anorexia/bulimia)
- Smoking cessation: start 1–2 weeks before quit date; continue for 7–12 weeks
Toxicity / Overdose
- Seizures are the primary concern in overdose (even at 2–3x therapeutic doses)
- Tachycardia, hypertension, agitation
- Unlike TCAs, QRS widening and cardiac arrest are rare
- Management: supportive, benzodiazepines for seizures; activated charcoal if early presentation
Discontinuation Syndrome
Mild — bupropion has a relatively low risk of discontinuation syndrome compared to SNRIs/SSRIs. The long half-life of its metabolites (20+ hours) provides a gradual natural taper. Nevertheless, abrupt stop can cause irritability, anxiety, and rarely sensory symptoms. A slow taper over 2–4 weeks is still recommended.
Recent Advances
- Auvelity® (bupropion + dextromethorphan, 2022): DXM is an NMDA receptor antagonist/sigma-1 agonist; bupropion inhibits CYP2D6, boosting DXM levels and preventing its rapid metabolism. This combination showed faster onset (~1 week) than traditional antidepressants in clinical trials. FDA approved for MDD in 2022.
- Contrave® (bupropion + naltrexone): FDA-approved for chronic weight management — exploits bupropion's dopaminergic effects on appetite/reward circuits with naltrexone's opioid blockade
- Growing evidence in treatment-resistant depression as an augmentation agent
- Cochrane Network Meta-Analysis (2023) confirms bupropion remains an effective pharmacotherapy for smoking cessation, though inferior to combination NRT and varenicline. (PMID 37696529)
PART III: SEROTONIN MODULATORS
This group shares serotonergic mechanisms but does NOT fit cleanly into the SSRI or SNRI categories — they each have additional receptor activities that define their clinical profiles.
1. TRAZODONE (Desyrel®, Oleptro®)
History
Trazodone was developed in Italy in the 1960s and introduced to the US market in 1981 — predating the SSRIs. It was among the most commonly prescribed antidepressants through the mid-1980s until SSRIs displaced it. Today its primary clinical use is as a hypnotic at low doses, while its antidepressant use at higher doses has largely fallen out of favor due to tolerability issues. (Goodman & Gilman's, p. 841)
Mechanism of Action — SARI (Serotonin Antagonist and Reuptake Inhibitor)
Trazodone has a complex, dose-dependent multimodal mechanism (Stahl's, p. 328):
- Potent 5-HT2A antagonism — the primary antidepressant mechanism
- 5-HT2C antagonism (at higher doses) — increases NE and DA release in PFC
- SERT inhibition (at higher doses, ≥300 mg/day) — serotonin reuptake blockade
- α1-adrenergic antagonism — causes sedation and orthostatic hypotension
- H1 histamine antagonism — sedation, weight gain
- α2 antagonism (mild) — disinhibits NE and 5-HT release
Its primary metabolite m-chlorophenylpiperazine (m-CPP) is a potent 5-HT2 agonist/antagonist and contributes to its effects.
The IR formulation given at bedtime (50–150 mg) exploits its sedating properties without significant serotonergic antidepressant effects.
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Bioavailability | ~65% (increases with food) |
| Protein binding | ~89–95% |
| Metabolism | CYP3A4 → m-CPP (active metabolite) |
| Half-life | ~6–9 hours (IR); longer with XR |
| Elimination | Urine (75%) and feces (25%) |
CYP3A4 inhibitors (ritonavir, ketoconazole) can substantially increase trazodone levels. (Katzung, p. 2784)
Formulations & Dosing
| Use | Formulation | Dose |
|---|---|---|
| Insomnia (off-label) | IR tablets | 50–100 mg at bedtime |
| Depression (adjunct) | IR tablets | 150–600 mg/day in divided doses |
| Depression | Oleptro® XR | 150–375 mg once nightly |
Indications
- FDA-approved: MDD
- Primary off-label use: Insomnia — most common current clinical use (not associated with dependence or tolerance, unlike BZDs or z-drugs)
- Off-label: Anxiety, PTSD nightmares, agitation in dementia, priapism-free alternative to other agents (ironically, trazodone itself causes priapism)
Contraindications
- MAOIs (serotonin syndrome)
- Recent MI (relative)
- Hypersensitivity
Side Effects
| Effect | Notes |
|---|---|
| Sedation | Major — often exploited therapeutically |
| Orthostatic hypotension, dizziness | Due to α1 blockade — fall risk |
| Nausea, dry mouth | Common |
| Priapism | Rare (1/6,000–1/10,000 men) but urologic emergency — requires immediate treatment; can result in impotence |
| Cardiac arrhythmias | Rare at therapeutic doses |
| Weight gain | Modest (H1 blockade) |
No sexual dysfunction and no anticholinergic effects are notable advantages. (Lippincott, p. 590)
Drug Interactions
- MAOIs: serotonin syndrome
- CYP3A4 inhibitors (ritonavir, azole antifungals): markedly increase trazodone levels
- CNS depressants: additive sedation
- Antihypertensives: additive hypotension
- Digoxin, phenytoin: trazodone may increase levels
Special Populations
- Elderly: preferred hypnotic due to no dependence/tolerance, but high fall risk from orthostasis; use lowest effective dose (25–50 mg)
- Priapism: educate all male patients — emergency if erection >4 hours
- Pregnancy: limited data; generally use cautiously
Discontinuation
Relatively mild discontinuation syndrome due to its moderate half-life and complex receptor profile. Taper if used long-term.
2. NEFAZODONE (Serzone®)
History
Nefazodone is a structural analog of trazodone developed by Bristol-Myers Squibb, approved in 1994. It was withdrawn from the market in most countries by 2003–2004 after reports of potentially fatal hepatotoxicity (including hepatic failure and death). It remains available as a generic in the US but is very rarely prescribed. (Goodman & Gilman's, p. 841)
Mechanism of Action — SARI
- 5-HT2A antagonism (primary) — same class as trazodone
- Weak SERT inhibition
- Metabolites hydroxynefazodone and m-CPA — both 5-HT receptor inhibitors
- Less sedating than trazodone — no significant H1 or α1 blockade at therapeutic doses
- No significant sexual dysfunction — due to absence of 5-HT2-mediated downstream effects
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Bioavailability | ~20% (extensive first-pass) |
| Protein binding | >99% |
| Metabolism | CYP3A4 (major) — and nefazodone is a potent CYP3A4 inhibitor |
| Half-life | ~2–4 hours (triazolo-dione metabolite: ~19 hours) |
| Elimination | Feces and urine |
Critical: Nefazodone is a potent CYP3A4 inhibitor — it can dramatically increase levels of CYP3A4 substrates (simvastatin, cyclosporine, triazolam, midazolam, cisapride, pimozide) with serious consequences.
Dosing
150–600 mg/day in divided doses (BID). Titrate carefully.
Hepatotoxicity (Black Box Warning)
- FDA black box warning issued in 2001
- Risk of serious hepatotoxicity: ~1/250,000–300,000 patient-years (about 3–4× the background rate)
- Can progress to fulminant hepatic failure requiring transplant
- Monitor LFTs; do not use if baseline LFTs elevated; discontinue at first sign of hepatic dysfunction
- This concern effectively ended its widespread use
Contraindications
- Active liver disease or elevated baseline LFTs (absolute)
- MAOIs
- Cisapride, pimozide, carbamazepine, triazolam (CYP3A4 interactions causing serious toxicity)
3. MIRTAZAPINE (Remeron®)
History
Mirtazapine (a piperazinoazepine) was developed in the Netherlands and approved by the FDA in 1996. It belongs to the class of NaSSA (Noradrenergic and Specific Serotonergic Antidepressant) agents. Closely related to mianserin (not available in the US).
Mechanism of Action — NaSSA (unique and complex)
Mirtazapine's mechanism is fundamentally different from reuptake inhibitors (Stahl's, p. 519–527):
-
α2-adrenergic receptor antagonism (presynaptic autoreceptors AND heteroceptors):
- Removes the "brake" on noradrenergic neurons → disinhibits NE release
- Also disinhibits serotonin release (α2 heteroceptors on 5-HT neurons)
- Net result: dual NE + 5HT enhancement without transporter blockade — functionally similar to SNRI but by a completely different mechanism ("cuts the brake cable" vs. "blocks the exhaust pipe")
-
5-HT2A antagonism — prevents sexual dysfunction, improves sleep architecture, potential antidepressant effect
-
5-HT2C antagonism — increases NE and DA release in PFC, antidepressant and anti-anxiolytic
-
5-HT3 antagonism — antiemetic (virtually no nausea with mirtazapine), disinhibits ACh and NE release
-
H1 histamine antagonism (potent) — causes sedation and weight gain (most problematic at low doses; paradoxically, higher doses may be less sedating due to stronger NE stimulation)
-
No anticholinergic effects (unlike TCAs)
The Paradox of Mirtazapine Dosing
- At 7.5–15 mg: predominantly H1 blockade → very sedating, increases appetite
- At 30–45 mg: H1 blockade is relatively less dominant due to increasing NE stimulation → less sedating, still effective
- The clinical implication: patients who complain of too much sedation may actually tolerate a dose increase better than a decrease — a counterintuitive but pharmacologically sound approach
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Bioavailability | ~50% |
| Protein binding | ~85% |
| Metabolism | CYP1A2, CYP2D6, CYP3A4 |
| Half-life | ~20–40 hours |
| Elimination | Urine (75%) and feces (15%) |
Long half-life → lower discontinuation syndrome severity.
Formulations & Dosing
- Tablets: 7.5 mg, 15 mg, 30 mg, 45 mg
- Orally disintegrating tablets (Remeron SolTab®): useful in patients unable to swallow
- Starting dose: 15 mg at bedtime
- Target dose: 30–45 mg at bedtime
- Always given at night due to sedation
- Generic widely available
Indications
- FDA-approved: MDD
- Off-label:
- Insomnia (unlabeled — widely used at 7.5–15 mg)
- Chemotherapy-induced nausea/vomiting (5-HT3 antagonism)
- Appetite stimulant in cancer, HIV/AIDS, elderly patients with weight loss
- Panic disorder, GAD (limited evidence)
- Augmentation in treatment-resistant depression (with SSRI/SNRI — "California rocket fuel" combo with venlafaxine)
- Migraine prevention (limited evidence)
Side Effects
| Effect | Notes |
|---|---|
| Sedation | Very common (exploit by giving at bedtime) |
| Weight gain | Significant — among the most weight-gaining antidepressants |
| Increased appetite | H1 + 5-HT2C mechanisms |
| Dry mouth | Common |
| Constipation | Common |
| Dizziness | Less common |
| No sexual dysfunction | Major advantage |
| No anticholinergic effects | Advantage over TCAs |
| Agranulocytosis | Rare (1/1,000) — monitor CBC if fever/infection develops |
Drug Interactions
- MAOIs: contraindicated
- CNS depressants (alcohol, benzos): additive sedation — avoid
- CYP1A2/2D6/3A4 inhibitors: may increase mirtazapine levels
- Minimal CYP enzyme inhibition — relatively low drug interaction potential compared to SSRIs
Special Populations
- Elderly: excellent choice when appetite stimulation and sedation are desirable; no anticholinergic effects; no orthostasis risk (unlike TCAs); but monitor for excessive sedation and fall risk
- Cancer patients: used as appetite stimulant and antiemetic
- Medically ill / patients with severe nausea: ideal (5-HT3 antagonism)
- Patients with SSRI-induced sexual dysfunction: switching to mirtazapine eliminates this
- Pregnancy: relatively limited data; appears safe; often preferred over SNRIs for morning sickness management (off-label)
Discontinuation
Mild syndrome — long half-life (20–40 hours) provides natural taper. However, sleep disruption, nausea, and anxiety can occur with abrupt cessation. Taper over 2–4 weeks.
4. VILAZODONE (Viibryd®)
History
Vilazodone was approved by the FDA in 2011 for MDD. It was designed as a hybrid SSRI + 5-HT1A partial agonist — the same mechanism as buspirone (5-HT1A partial agonist) combined with SSRI activity. This dual mechanism was hypothesized to reduce the delayed onset and reduce sexual dysfunction seen with SSRIs.
Mechanism of Action
- SERT inhibition (primary) — same as SSRIs
- 5-HT1A partial agonism — stimulates somatodendritic autoreceptors in the raphe nucleus AND postsynaptic 5-HT1A receptors
- Postsynaptic 5-HT1A agonism may contribute additional antidepressant and anxiolytic effects
- May reduce sexual dysfunction by partially blocking downstream serotonergic activation
The extent to which the 5-HT1A activity adds above SSRI-alone effects remains clinically debated. (Lippincott, p. 589)
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Bioavailability | ~72% (must be taken with food — food increases AUC by ~147%) |
| Protein binding | ~96–99% |
| Metabolism | CYP3A4 (primary) |
| Half-life | ~25 hours |
| Elimination | Feces (>58%), urine (1%) |
Must be taken with food — absorption is significantly reduced in fasted state.
Formulations & Dosing
- Tablets: 10 mg, 20 mg, 40 mg
- Starter pack titration:
- Days 1–7: 10 mg once daily with food
- Days 8–14: 20 mg once daily with food
- Day 15 onward: 40 mg once daily with food
- Dose adjustments: reduce to 20 mg with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole)
Indications
- FDA-approved: MDD only
- No FDA-approved anxiety indications (despite mechanism suggesting anxiolytic benefit)
Side Effects
Similar to SSRIs: nausea, diarrhea (very common), sexual dysfunction (less than SSRIs but still present), dizziness, headache. GI side effects (particularly diarrhea) are notably prominent — possibly due to 5-HT1A agonism in the GI tract.
Contraindications
- MAOIs
- Strong CYP3A4 inducers may reduce efficacy
Discontinuation
Risk exists due to 25-hour half-life. Taper gradually.
5. VORTIOXETINE (Trintellix®)
History
Vortioxetine was developed by Lundbeck/Takeda and approved by the FDA in 2013 (originally as Brintellix®, renamed Trintellix® in 2016 to avoid confusion with the antiplatelet Brilinta®). It represents a significant pharmacological advance as a multimodal serotonergic antidepressant with pro-cognitive effects not seen with other antidepressants.
Mechanism of Action — Multimodal Serotonergic Agent (Katzung, p. 2847; Stahl's, p. 329)
Vortioxetine has seven distinct serotonergic mechanisms simultaneously:
| Action | Receptor/Transporter | Effect |
|---|---|---|
| Reuptake inhibition | SERT | ↑ synaptic 5-HT |
| Agonist | 5-HT1A | Activates autoreceptors + postsynaptic → antidepressant/anxiolytic |
| Partial agonist | 5-HT1B | Modulates 5-HT release |
| Antagonist | 5-HT1D | Disinhibits 5-HT release |
| Antagonist | 5-HT3 | ↑ ACh, NE release (disinhibits glutamate) → pro-cognitive |
| Antagonist | 5-HT7 | Modulates mood, circadian rhythm, cognitive flexibility |
| Antagonist | 5-HT2A | Improves sleep, mood |
The 5-HT3 and 5-HT7 antagonism are believed to underlie vortioxetine's unique pro-cognitive profile:
- 5-HT3 antagonism on GABA interneurons → disinhibits pyramidal neurons → ↑ glutamate, ACh, NE output (cognitive enhancement)
- Vortioxetine improves performance on the DSST (Digit Symbol Substitution Test) — a measure of processing speed — better than any other antidepressant tested (Stahl's, p. 329)
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Bioavailability | ~75% |
| Protein binding | ~98% |
| Metabolism | CYP2D6 (primary), also CYP3A4, CYP2C9 → inactive metabolites (then glucuronide conjugation) |
| Half-life | ~66 hours (long!) |
| Elimination | Urine (59%) and feces (26%) |
Long half-life (66 hours) → lower discontinuation syndrome risk than most antidepressants. (Katzung, p. 2784)
Formulations & Dosing
- Tablets: 5 mg, 10 mg, 20 mg
- Starting dose: 10 mg once daily
- Target dose: 20 mg once daily (superior evidence for cognitive benefit at 20 mg)
- Dose reduction: to 10 mg/day with strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion)
- Can be taken with or without food
Indications
- FDA-approved: MDD
- European approval: Cognitive dysfunction associated with depression
- Off-label: Treatment-resistant depression (augmentation), anxiety, Parkinson's disease with depression (open-label data showing cognitive benefit)
Contraindications
- MAOIs
- Hypersensitivity
Side Effects
| Effect | Notes |
|---|---|
| Nausea | Most common — dose-related, often transient |
| Constipation | Common |
| Sexual dysfunction | Lower than SSRIs; present but moderate |
| Vomiting, dizziness | Less common |
| Cognitive enhancement | Positive effect — improved processing speed, executive function, and verbal learning |
| Headache | Less common |
Notable: less sexual dysfunction than SSRIs, no weight gain, and no sedation — excellent tolerability profile.
Drug Interactions
- MAOIs: contraindicated
- Strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion): increase vortioxetine levels — reduce dose to 10 mg/day
- Strong CYP2D6 inducers (rifampin): decrease levels — may increase dose to 3× original dose (max 60 mg/day with inducers in trials)
- Serotonergic drugs: additive serotonin syndrome risk
Special Populations
- Elderly: particularly well-suited due to pro-cognitive effects and low side effect burden; no anticholinergic effects; no significant cardiac effects; may require lower starting dose
- Parkinson's disease with depression: open-label studies show benefit on both mood and cognition
- Patients with cognitive symptoms of depression: considered first-line by many clinicians given pro-cognitive profile
- Pregnancy: limited human data; animal studies show no teratogenicity; use caution
Discontinuation
Minimal — the 66-hour half-life means very gradual natural tapering; discontinuation syndrome is uncommon and mild compared to venlafaxine or paroxetine. Still taper over 2–4 weeks if possible.
Recent Advances
- CONNECT study and FOCUS trial: established vortioxetine's cognitive benefit as superior to duloxetine and placebo on DSST in MDD patients
- Ongoing investigation of its role in cognitive symptoms of bipolar depression and MCI associated with Alzheimer's disease
- May be pro-cognitive even beyond its antidepressant effects — potential role in broader cognitive impairment conditions
COMPREHENSIVE COMPARISON TABLE
| Property | Venlafaxine | Desvenlafaxine | Duloxetine | Levomilnacipran | Bupropion | Trazodone | Mirtazapine | Vilazodone | Vortioxetine |
|---|---|---|---|---|---|---|---|---|---|
| Class | SNRI | SNRI | SNRI | SNRI | NDRI | SARI | NaSSA | SSRI + 5HT1A PA | Multimodal |
| Half-life | 5–11 h | 11 h | 12 h | 12 h | 21 h (XL) | 6–9 h | 20–40 h | 25 h | 66 h |
| CYP metabolism | 2D6 | Conjugation | 1A2, 2D6 | 3A4 | 2B6 | 3A4 | 1A2,2D6,3A4 | 3A4 | 2D6, 3A4 |
| Sexual dysfunction | ++ | ++ | ++ | ++ | + (low) | + (low) | + (low) | + (low) | + (moderate) |
| Sedation | + | + | + | + | - | +++ | +++ | + | - |
| Weight gain | neutral | neutral | neutral | neutral | - (loss) | + | +++ | neutral | neutral |
| Nausea | +++ | ++ | +++ | ++ | + | ++ | + | +++ | ++ |
| BP elevation | ++ (dose) | + | + | ++ | + | - | - | - | - |
| Seizure risk | low | low | low | low | ++ (dose) | low | low | low | low |
| Discontinuation syndrome | Severe | Moderate | Moderate | Moderate | Mild | Mild | Mild | Moderate | Mild |
| Pain indications | Yes (off-label) | No | Yes (FDA) | No | No | No | No | No | No |
| Smoking cessation | No | No | No | No | Yes (FDA) | No | No | No | No |
| Cognitive benefit | Modest | No | Modest (elderly) | No | No | No | No | No | Superior (FDA EU) |
| Key risk | BP elevation | — | Hepatotoxicity | Tachycardia | Seizures | Priapism | Agranulocytosis | Diarrhea | — |
DISCONTINUATION SYNDROMES — CLASS-WIDE SUMMARY
The term "discontinuation syndrome" is increasingly recognized as pharmacologically inadequate — "withdrawal syndrome" is now preferred by NICE (UK), the British Medical Association, and Royal College of Psychiatrists. (Maudsley Deprescribing Guidelines)
Mnemonic: FINISH (primarily for SSRIs/SNRIs)
- Flu-like symptoms
- Insomnia
- Nausea and GI symptoms
- Imbalance/dizziness
- Sensory disturbances ("brain zaps," electric shocks, paresthesias)
- Hyperactivation/anxiety/irritability
Risk factors for severe syndrome:
- Short half-life (venlafaxine IR, paroxetine > venlafaxine XR > desvenlafaxine)
- Longer duration of treatment
- Higher dose
- Abrupt discontinuation
- History of previous discontinuation symptoms
Management:
- Never stop abruptly after >4 weeks of treatment
- Taper: reduce by 10–25% every 2–4 weeks at minimum
- For severe cases: hyperbolic tapering (Horowitz-Taylor model) — exponentially smaller reductions as dose decreases
- Bridging strategy: switch to fluoxetine (half-life 1–6 days including active metabolite norfluoxetine) and taper fluoxetine
- Symptoms vs. relapse: distinguish by temporal relationship (syndrome appears within 2–7 days; relapse develops more gradually over 2+ weeks)
- Neonates born to mothers on TCAs may experience serious, potentially life-threatening withdrawal — monitor neonates of mothers on antidepressants (Rosen's Emergency Medicine, p. 890)
SEROTONIN SYNDROME vs. DISCONTINUATION SYNDROME
| Feature | Serotonin Syndrome | Discontinuation Syndrome |
|---|---|---|
| Cause | Too much serotonin (drug combinations) | Too little serotonin (abrupt stop) |
| Onset | Hours after adding a drug | 24–72 hours after last dose |
| Neuromuscular | Clonus, hyperreflexia, myoclonus | Absent |
| Vitals | Hyperthermia, tachycardia | Mild/absent |
| GI | Diarrhea | Nausea, diarrhea |
| Sensory | Agitation | "Brain zaps," paresthesias |
| Severity | Can be fatal | Rarely life-threatening |
| Treatment | Cyproheptadine, benzos, supportive | Restart and taper |
SPECIAL POPULATIONS — SUMMARY
Pregnancy
- No SNRI or serotonin modulator is a proven major teratogen (2022 meta-analysis)
- Neonatal adaptation syndrome possible in all serotonergic drugs (jitteriness, mild respiratory distress, poor feeding — resolves within days)
- Persistent pulmonary hypertension of the newborn (PPHN): rare but reported association with SSRIs/SNRIs in third trimester
- Risk-benefit must be individualized — untreated maternal depression also harms fetal outcomes
Elderly
- Hyponatremia (SIADH): risk with all SNRIs/SSRIs; monitor serum sodium baseline and 2–4 weeks post-initiation
- Falls: sedating agents (mirtazapine, trazodone) and orthostatic hypotensors increase fall risk
- Mirtazapine and vortioxetine are preferred in elderly for favorable profiles (no anticholinergic, pro-cognitive, pro-appetite)
- Reduce starting doses; titrate slowly
Hepatic Impairment
- Duloxetine: avoid entirely in hepatic impairment or alcohol use
- Nefazodone: contraindicated with elevated LFTs
- Trazodone: use cautiously; metabolized by CYP3A4
- Bupropion: extended half-life of metabolites; reduce dose and frequency
Renal Impairment
- Milnacipran and levomilnacipran: primarily renally eliminated; dose-reduce in moderate-severe impairment
- Desvenlafaxine: dose-reduce or extend dosing interval in severe impairment
- Mirtazapine, vortioxetine: no major dose adjustments needed for mild-moderate impairment
GUIDELINES & CLINICAL USE
- APA Practice Guidelines (MDD): SNRIs and SSRIs are first-line pharmacotherapy for MDD. Choice based on side effect profile, patient history, comorbidities, cost
- NICE Guidelines (UK, 2022): Updated to acknowledge severity and duration of antidepressant withdrawal; recommend slower tapering protocols
- Fibromyalgia: duloxetine and milnacipran — Level A evidence (FDA-approved); SNRIs recommended in all major rheumatology guidelines
- Diabetic peripheral neuropathy: duloxetine is first-line (FDA-approved); venlafaxine second-line
- GAD: venlafaxine XR, duloxetine — both FDA-approved; first-line with SSRIs
- Smoking cessation (NICE/APA): bupropion SR is an established second-line pharmacotherapy (after varenicline); Cochrane 2023 confirms efficacy with combination NRT superior overall (PMID 37696529)
- Cognitive dysfunction in MDD: vortioxetine preferred (European label includes this indication)
- Postpartum depression insomnia: trazodone widely used off-label; mirtazapine also used
Sources: Stahl's Essential Psychopharmacology (Neuroscientific Basis) | Goodman & Gilman's Pharmacological Basis of Therapeutics, 13th ed. | Kaplan & Sadock's Comprehensive Textbook of Psychiatry | Lippincott Illustrated Reviews: Pharmacology, 8th ed. | Katzung's Basic & Clinical Pharmacology, 16th ed. | Maudsley Prescribing Guidelines in Psychiatry, 15th ed. | Maudsley Deprescribing Guidelines | Rosen's Emergency Medicine, 9th ed.
Recent evidence: Cochrane Network Meta-Analysis on smoking cessation pharmacotherapy [PMID 37696529, 2023] | SNRI hyponatremia systematic review [PMID 40764948, 2025]
---Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
Youjust provided the whole chatto me and now you are removing it…i did not even ask any new question
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.